DIOSynVax is revolutionizing vaccine antigen payload development
DIOSynVax customises vaccine antigen design to maximise the protection that vaccines can provide worldwide against existing and future viruses. Grounded firmly in virus structure and evolution, our method is patent protected, combining computational biology with in vitro and in vivo validation, selecting the best Vaccine Antigen Payload (VAP) candidates while growing a reservoir of data that continually improves our designs.
Collaborators
We partner with leading organisations to advance innovative vaccine solutions and protect global health
Latest News
Stay informed with the latest updates from DIOSynVax, including advancements in our vaccine development programs, strategic partnerships, and industry insights.
August 2026
DIOSynVax brings together genomics, synthetic biology, artificial intelligence (AI), and immunology to design broadly protective vaccine antigens that are compatible with most vaccine delivery systems.
August 2026
The first human clinical trial of a universal Sarbeco coronavirus vaccine has shown that the vaccine is safe and has no significant side-effects.
July 2026
The AI Discovery Awards are a core part of Nebius’ commitment to supporting startups develop AI apps in healthcare and life sciences.